Although a single CLL-specific genomic aberration has not been identified, ≥80% of CLL cases do exhibit chromosomal abnormalities. 7 Four common genomic alterations exist and include aberrations on ...
A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at ...
Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...
*p < 0.001; **p < 0.0001; ***p = 0.01; ****p < 0.01 vs comparator regimen.CClR: Cyclophosphamide + cladribine + rituximab; ClR: Cladribine + rituximab; CR: Complete ...
DUBLIN--(BUSINESS WIRE)--The "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Relapsed Chronic Lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback